Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach.

Katona G, Balogh GT, Dargó G, Gáspár R, Márki Á, Ducza E, Sztojkov-Ivanov A, Tömösi F, Kecskeméti G, Janáky T, Kiss T, Ambrus R, Pallagi E, Szabó-Révész P, Csóka I.

Pharmaceutics. 2020 Jan 25;12(2). pii: E97. doi: 10.3390/pharmaceutics12020097.

2.

Selected papers of the "12th central European symposium on pharmaceutical technology and regulatory affairs".

Csóka I, Regdon G Jr, Sovány T, Dreu R.

Eur J Pharm Sci. 2020 Jan 23;145:105238. doi: 10.1016/j.ejps.2020.105238. [Epub ahead of print] No abstract available.

PMID:
31982485
3.

Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease.

Akel H, Ismail R, Csóka I.

Eur J Pharm Biopharm. 2020 Mar;148:38-53. doi: 10.1016/j.ejpb.2019.12.014. Epub 2020 Jan 8. Review.

PMID:
31926222
4.

Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach.

Manteghi R, Pallagi E, Olajos G, Csóka I.

Eur J Pharm Sci. 2020 Mar 1;144:105197. doi: 10.1016/j.ejps.2019.105197. Epub 2019 Dec 17.

PMID:
31862311
5.

Investigation of Silicone-Containing Semisolid in Situ Film-Forming Systems Using QbD Tools.

Kis N, Kovács A, Budai-Szűcs M, Gácsi A, Csányi E, Csóka I, Berkó S.

Pharmaceutics. 2019 Dec 7;11(12). pii: E660. doi: 10.3390/pharmaceutics11120660.

6.

Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability.

Ismail R, Bocsik A, Katona G, Gróf I, Deli MA, Csóka I.

Pharmaceutics. 2019 Nov 12;11(11). pii: E599. doi: 10.3390/pharmaceutics11110599.

7.

Preparation and investigation of core-shell nanoparticles containing human interferon-α.

Kristó K, Szekeres M, Makai Z, Márki Á, Kelemen A, Bali L, Pallai Z, Dékány I, Csóka I.

Int J Pharm. 2020 Jan 5;573:118825. doi: 10.1016/j.ijpharm.2019.118825. Epub 2019 Nov 9.

PMID:
31715360
8.

Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook.

Sabir F, Ismail R, Csoka I.

Drug Discov Today. 2020 Jan;25(1):185-194. doi: 10.1016/j.drudis.2019.10.005. Epub 2019 Oct 17. Review.

PMID:
31629966
9.

3D-printed electrospinning setup for the preparation of loratadine nanofibers with enhanced physicochemical properties.

Ambrus R, Alshweiat A, Csóka I, Ovari G, Esmail A, Radacsi N.

Int J Pharm. 2019 Aug 15;567:118455. doi: 10.1016/j.ijpharm.2019.118455. Epub 2019 Jun 21.

PMID:
31233846
10.

Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery.

Ismail R, Sovány T, Gácsi A, Ambrus R, Katona G, Imre N, Csóka I.

Pharm Res. 2019 May 13;36(7):99. doi: 10.1007/s11095-019-2620-9.

11.

Application of the QbD-based approach in the early development of liposomes for nasal administration.

Pallagi E, Jójárt-Laczkovich O, Németh Z, Szabó-Révész P, Csóka I.

Int J Pharm. 2019 May 1;562:11-22. doi: 10.1016/j.ijpharm.2019.03.021. Epub 2019 Mar 13.

PMID:
30877028
12.

Development of Topical Nanocarriers for Skin Cancer Treatment Using Quality by Design Approach.

Csányi E, Bakonyi M, Kovács A, Budai-Szűcs M, Csóka I, Berkó S.

Curr Med Chem. 2019;26(35):6440-6458. doi: 10.2174/0929867325666181116143713. Review.

PMID:
30444194
13.

Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer.

Bíró T, Horvát G, Budai-Szűcs M, Csányi E, Urbán E, Facskó A, Szabó-Révész P, Csóka I, Aigner Z.

Drug Des Devel Ther. 2018 Aug 15;12:2529-2537. doi: 10.2147/DDDT.S165693. eCollection 2018.

14.

Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.

Bartos C, Pallagi E, Szabó-Révész P, Ambrus R, Katona G, Kiss T, Rahimi M, Csóka I.

Eur J Pharm Sci. 2018 Oct 15;123:475-483. doi: 10.1016/j.ejps.2018.07.061. Epub 2018 Aug 1.

PMID:
30076956
15.

Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.

Alshweiat A, Katona G, Csóka I, Ambrus R.

Eur J Pharm Sci. 2018 Sep 15;122:94-104. doi: 10.1016/j.ejps.2018.06.010. Epub 2018 Jun 14.

PMID:
29908301
16.

Optimization of the Critical Parameters of the Spherical Agglomeration Crystallization Method by the Application of the Quality by Design Approach.

Gyulai O, Kovács A, Sovány T, Csóka I, Aigner Z.

Materials (Basel). 2018 Apr 20;11(4). pii: E635. doi: 10.3390/ma11040635.

17.

Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes.

Csóka I, Pallagi E, Paál TL.

Drug Discov Today. 2018 Jul;23(7):1340-1343. doi: 10.1016/j.drudis.2018.03.012. Epub 2018 Mar 27. Review.

PMID:
29601866
18.

Patients' knowledge on oral anticoagulant treatment in Hungary.

Viola R, Fekete H, Csoka I.

Int J Clin Pharm. 2017 Dec;39(6):1265-1272. doi: 10.1007/s11096-017-0544-1. Epub 2017 Oct 19.

PMID:
29052116
19.

Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.

Karimi K, Katona G, Csóka I, Ambrus R.

J Pharm Biomed Anal. 2018 Jan 30;148:73-79. doi: 10.1016/j.jpba.2017.09.019. Epub 2017 Sep 22.

PMID:
28965047
20.

Preliminary study of nanonized lamotrigine containing products for nasal powder formulation.

Gieszinger P, Csóka I, Pallagi E, Katona G, Jójárt-Laczkovich O, Szabó-Révész P, Ambrus R.

Drug Des Devel Ther. 2017 Aug 23;11:2453-2466. doi: 10.2147/DDDT.S138559. eCollection 2017.

Supplemental Content

Loading ...
Support Center